Evidence map›Paper›PMID 24332429›Full record

ArticleLeukemia research2014

G0S2--a new player in leukemia.

Kimberly J Payne, Sinisa Dovat

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kimberly J PayneCenter for Health Disparities and Molecular Medicine, Department of Pathology and Human Anatomy, Loma Linda University School of Medicine, 1st floor Mortensen Hall, 11085 Campus St., Loma Linda, CA 92350, USA. Electronic address: kpayne@llu.edu.
Sinisa DovatDepartment of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Pennsylvania State University · US

Funding

NIH-LLU Initiative for Maximizing Student DiversityR25GM060507 · NIGMS · LOMA LINDA UNIVERSITY · PI DE LEON, MARINO · 2001 to 2022
$11.3M
The role of imidazoline receptor in type-2 diabetesP20MD001632 · NIMHD · LOMA LINDA UNIVERSITY · PI DE LEON, DAISY D. · 2005 to 2009
$8.0M
Research Training/Education CoreP20MD006988 · NIMHD · LOMA LINDA UNIVERSITY · PI CASIANO, CARLOS A. · 2012 to 2016
$6.2M
The Role of Zinc Finger Genes in LeukemogenesisR01HL095120 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI DOVAT, SINISA · 2009 to 2013
$1.8M
Xenograft Model to Study Impact of CRLF2-Ligand in Hispanic Childhood B-ALLR21CA162259 · NCI · LOMA LINDA UNIVERSITY · PI PAYNE, KIMBERLY J · 2012 to 2013
$346k
Development of novel small molecule drugs for the treatment of high risk B-ALLR43CA165739 · NCI · NOVOMEDIX, INC. · PI PAYNE, KIMBERLY J, SWINDLEHURST, CATHY A · 2012 to 2013
$296k
NCI NIH HHS R21 CA162259NCI NIH HHS R43 CA165739NHLBI NIH HHS R01 HL095120NIGMS NIH HHS R25 GM060507NIMHD NIH HHS P20 MD001632NIMHD NIH HHS P20 MD006988NIMHD NIH HHS P20MD006988
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cell ProliferationAnimalsCell Cycle ProteinsCytosolHumansNucleolinPhosphoproteinsRNA-Binding ProteinsCell Cycle ProteinsG0S2 protein, humanNucleolinPhosphoproteinsRNA-Binding ProteinsCMLG0S2K562LeukemiaTumor suppressor

Identifiers

PMID24332429
PMCPMC4370841
OpenAlexW1964292362

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.